Plexiform Neurofibroma Treatment Market Report 2026

The plexiform neurofibroma treatment market size has grown strongly in recent years. It will grow from $1.45 billion in 2025 to $1.57 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to limited treatment options for complex nerve sheath tumors, reliance on surgical intervention for symptom relief, low disease awareness and diagnosis rates, high treatment costs, limited availability of specialized care centers.

The plexiform neurofibroma treatment market size is expected to see strong growth in the next few years. It will grow to $2.14 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to advancements in targeted and precision therapies, increasing clinical research and drug approvals, growing awareness of rare genetic disorders, expansion of pediatric oncology services, integration of personalized treatment planning. Major trends in the forecast period include rising adoption of targeted therapies for tumor control, increasing use of minimally invasive and robotic surgeries, growing focus on pediatric patient-specific treatment approaches, expansion of combination therapy protocols, improved symptom management and quality of life outcomes.

The growing demand for personalized medicine is anticipated to drive the growth of the plexiform neurofibroma treatment market in the coming years. Personalized medicine involves tailoring medical treatment based on a patient’s genetic makeup and molecular characteristics, enabling therapies that are highly specific to individual tumor biology and genetic alterations. The expansion of personalized medicine is fueled by an increasing focus on rare disease populations and mutation-specific therapies. Rising demand for personalized medicine is accelerating progress in plexiform neurofibroma treatment by encouraging the development of targeted therapies and precision-based strategies that customize interventions according to the distinct genetic and molecular profiles of individual patients, thereby improving treatment effectiveness, reducing adverse effects, and addressing variability in tumor presentation. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based professional membership organization, the U.S. Food and Drug Administration approved 26 new personalized treatments, including 20 molecular entities and six gene- or cell-based therapies, with 16 targeting rare diseases - more than double the six approvals recorded in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the plexiform neurofibroma treatment market.

Major companies operating in the plexiform neurofibroma treatment market are concentrating on the development of advanced therapeutic options, such as small-molecule inhibitors, to improve treatment outcomes. Small-molecule inhibitors are low-molecular-weight compounds designed to block specific proteins or enzymes involved in abnormal cellular signaling pathways. For instance, in February 2025, SpringWorks Therapeutics, a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration had approved Gomekli, an oral small-molecule MEK inhibitor. Gomekli is indicated for the treatment of adults and children aged two years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas that cannot be fully removed through surgery. Clinical trial results showed that 41% of adult patients and 52% of pediatric patients achieved a confirmed reduction in tumor size, with an average tumor volume reduction of 41% in adults and 42% in children. In addition, responses lasting at least 12 months were observed in 88% of adults and 90% of children, with nearly half of patients in both groups maintaining their response for more than 24 months.

In April 2025, Merck Group, a Germany-based pharmaceutical company, acquired SpringWorks Therapeutics for $3.4 billion. Through this acquisition, Merck aims to strengthen its healthcare business revenues, accelerate medium- to long-term growth, and expand its presence in the U.S. market. The transaction significantly enhances Merck’s portfolio in rare tumors and rare diseases, as SpringWorks contributes two FDA-approved therapies - Ogsiveo for the treatment of desmoid tumors and Gomekli for neurofibromatosis type 1-associated plexiform neurofibromas. SpringWorks Therapeutics is a US-based biopharmaceutical company specializing in treatments for plexiform neurofibroma.

Major companies operating in the plexiform neurofibroma treatment market are SpringWorks Therapeutics, AstraZeneca, Roche Holding AG, Novartis AG, Bayer AG, Eli Lilly and Company, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., AbbVie Inc., Merck KGaA, Ipsen Pharma, Bristol-Myers Squibb, BioMarin Pharmaceutical Inc., Sangamo Therapeutics, Recursion Pharmaceuticals, Day One Biopharmaceuticals, BridgeBio Pharma, Loxo Oncology (Eli Lilly subsidiary), Blueprint Medicines, Kura Oncology, Exelixis Inc., Natera Inc., Amgen Inc., Taiho Pharmaceutical Co. Ltd., Zai Lab Limited, Innovent Biologics, BeiGene Ltd., Deciphera Pharmaceuticals, Cullinan Oncology.

North America was the largest region in the plexiform neurofibroma treatment market in 2025. The regions covered in the plexiform neurofibroma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plexiform neurofibroma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the plexiform neurofibroma treatment market by increasing the cost of imported pharmaceutical ingredients, advanced surgical equipment, and radiation therapy systems. Targeted therapy drugs and robotic surgery segments are most affected, particularly in regions dependent on imports such as Asia-Pacific and parts of Latin America. These cost pressures can slow treatment adoption and increase healthcare expenditure. However, tariffs also encourage local drug manufacturing, regional clinical research, and domestic production of medical technologies, supporting long-term market growth.

The plexiform neurofibroma treatment market research report is one of a series of new reports that provides plexiform neurofibroma treatment market statistics, including plexiform neurofibroma treatment industry global market size, regional shares, competitors with a plexiform neurofibroma treatment market share, detailed plexiform neurofibroma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the plexiform neurofibroma treatment industry. This plexiform neurofibroma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Plexiform neurofibroma treatment encompasses medical strategies focused on managing and controlling the growth of complex nerve sheath tumors. The objective is to alleviate symptoms, minimize complications, and enhance quality of life by addressing the effects of the tumor on surrounding tissues and structures.

The main types of treatments for plexiform neurofibroma include surgery, radiation therapy, chemotherapy, and targeted therapy. Surgery is a medical specialty that involves treating injuries, diseases, or other health conditions through manual and instrumental procedures, often requiring incisions to remove, repair, or examine tissues or organs. It is applied for indications such as pain control, tumor reduction, and restoration of function in both pediatric and adult patients. These treatments are utilized by various end users, including hospitals, clinics, and homecare settings.

The plexiform neurofibroma treatment market consists of revenues earned by entities by providing services such as genetic testing, clinical evaluation, multidisciplinary care coordination, and clinical trial management. The market value includes the value of related goods sold by the service provider or included within the service offering. The plexiform neurofibroma treatment market also includes sales of tumor monitoring kits, genetic testing kits, clinical decision support tools, and rehabilitation aids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.